- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
GlaxoSmithKline to buy eczema drug
Author(s):
Pharmaceutical company GlaxoSmithKline, based here, has agreed to purchase new eczema treatment Toctino (alitretinoin) for a reported $300 million.
London - Pharmaceutical company GlaxoSmithKline, based here, has agreed to purchase new eczema treatment Toctino (alitretinoin) for a reported $300 million.
The Independent of London reports that under terms of the agreement, GlaxoSmithKline will pay the drug’s Swiss developer, Basilea, about $146 million and additional payments of about $75 million if the drug wins approval in the United States. Basilea is also entitled to payments on any U.S. sales from three years after its launch.
Toctino is sold in 14 countries and is in phase 3 clinical trials in the United States, The Independent reports.
Go back to the Dermatology Times eNews newsletter.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
